BBP
Virtus LifeSci Biotech Products ETF·ARCA
--
--(--)
--
--(--)
Key Stats
Assets Under Management
43.70MUSD
Fund Flows (1Y)
14.48MUSD
Dividend Yield
--
Discount/Premium to NAV
0.01%
Shares Outstanding
550.00K
Expense Ratio
0.79%
About Virtus LifeSci Biotech Products ETF
Issuer
Virtus Investment Advisers, LLC
Brand
Virtus
Home Page
Inception Date
Dec 16, 2014
Structure
Open-Ended Fund
Index Tracked
LifeSci Biotechnology Products Index
Management Style
Passive
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
Virtus Advisers LLC
Distributor
VP Distributors LLC
BBP offers a different approach to biotech investing by handpicking firms whose lead drugs are on its product stage or those firms that have attained FDA approval for their leading drug. Stocks must earn a majority of their revenue from the research and development and/or marketing and sale of novel drugs or other therapeutics used in the treatment of human diseases. The fund is offered by BioShares alongside launched a sister fund, BBC, which targets biotech firms in the clinical trial stage. The index is reconstituted on a semi-annual basis.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Biotechnology
Strategy
Equal
Geography
U.S.
Weighting Scheme
Equal
Selection Criteria
Proprietary
Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Holdings
Symbol
Ratio
Dynavax Technologies Corp
2.23%
Amicus Therapeutics Inc
2.11%
Iovance Biotherapeutics Inc
1.97%
Mirum Pharmaceuticals Inc
1.90%
Phathom Pharmaceuticals Inc
1.82%
BioMarin Pharmaceutical Inc
1.73%
Symbol
Ratio
Day One Biopharmaceuticals Inc
1.72%
Halozyme Therapeutics Inc
1.70%
Travere Therapeutics Inc
1.69%
Exelixis Inc
1.68%
Top 10 Weight 18.55%
10 Total Holdings
See all holdings
Related Funds
Seasonals
Volume Profile
Trade Flow Insight
Community Forum
Loading...
Related News
No articles available
You can ask Aime
No Data
